GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » Cyclically Adjusted PB Ratio

Bio-Techne (FRA:TE1) Cyclically Adjusted PB Ratio : 8.48 (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne Cyclically Adjusted PB Ratio?

As of today (2024-05-21), Bio-Techne's current share price is €76.50. Bio-Techne's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €9.02. Bio-Techne's Cyclically Adjusted PB Ratio for today is 8.48.

The historical rank and industry rank for Bio-Techne's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:TE1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.02   Med: 7.49   Max: 19.03
Current: 8.45

During the past years, Bio-Techne's highest Cyclically Adjusted PB Ratio was 19.03. The lowest was 5.02. And the median was 7.49.

FRA:TE1's Cyclically Adjusted PB Ratio is ranked worse than
88.12% of 648 companies
in the Biotechnology industry
Industry Median: 1.745 vs FRA:TE1: 8.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Bio-Techne's adjusted book value per share data for the three months ended in Mar. 2024 was €11.762. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €9.02 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bio-Techne Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted PB Ratio Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.14 10.65 15.91 10.46 8.97

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.37 8.97 7.29 8.16 7.21

Competitive Comparison of Bio-Techne's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PB Ratio falls into.



Bio-Techne Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bio-Techne's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=76.50/9.02
=8.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Bio-Techne's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.762/131.7762*131.7762
=11.762

Current CPI (Mar. 2024) = 131.7762.

Bio-Techne Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.955 100.560 5.183
201409 4.157 100.428 5.455
201412 4.484 99.070 5.964
201503 5.099 99.621 6.745
201506 5.078 100.684 6.646
201509 5.020 100.392 6.589
201512 5.284 99.792 6.978
201603 5.148 100.470 6.752
201606 5.252 101.688 6.806
201609 5.347 101.861 6.917
201612 5.657 101.863 7.318
201703 5.685 102.862 7.283
201706 5.656 103.349 7.212
201709 5.382 104.136 6.811
201712 5.626 104.011 7.128
201803 5.715 105.290 7.153
201806 6.140 106.317 7.610
201809 6.288 106.507 7.780
201812 6.385 105.998 7.938
201903 6.707 107.251 8.241
201906 6.798 108.070 8.289
201909 6.999 108.329 8.514
201912 7.778 108.420 9.454
202003 7.663 108.902 9.273
202006 7.974 108.767 9.661
202009 7.914 109.815 9.497
202012 8.068 109.897 9.674
202103 8.321 111.754 9.812
202106 8.325 114.631 9.570
202109 8.870 115.734 10.099
202112 9.583 117.630 10.735
202203 9.912 121.301 10.768
202206 10.278 125.017 10.834
202209 11.271 125.227 11.861
202212 10.979 125.222 11.554
202303 11.218 127.348 11.608
202306 11.514 128.729 11.787
202309 11.821 129.860 11.995
202312 11.458 129.419 11.667
202403 11.762 131.776 11.762

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bio-Techne  (FRA:TE1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bio-Techne Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (FRA:TE1) Business Description

Industry
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (FRA:TE1) Headlines

No Headlines